利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

348 条记录 (耗时 0.04 秒)

    Compositions and Methods for Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes
    83.
    发明申请
    Compositions and Methods for Generation of Infectious Hepatitis C Virus in Immortalized Human Hepatocytes 审中-公开
    在永生化人肝细胞中产生传染性丙型肝炎病毒的组合物和方法

    公开(公告)号：US20090148832A1

    公开(公告)日：2009-06-11

    申请号：US12365523

    申请日：2009-02-04

    申请人： RATNA RAY ,  RANJIT RAY ,  ARNAB BASU ,  TATSUO KANDA

    发明人： RATNA RAY ,  RANJIT RAY ,  ARNAB BASU ,  TATSUO KANDA

    IPC分类号： C12Q1/70 ,  C12N7/00

    CPC分类号： C12N7/00 ,  A61K2039/525 ,  C12N2770/24251 ,  C12Q1/18 ,  G01N33/5067 ,  G01N2333/18

    摘要： The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.

    摘要翻译： 本发明提供了一种在培养中能够产生感染性丙型肝炎病毒1a（HCV1a）颗粒的细胞系。 公开了能够在培养中产生感染性HCV 1a病毒颗粒的HCV 1a（克隆H77）转染的永生人肝细胞（IHH）的组合物和方法。 还公开了使用细胞系或源自所述细胞系的HCV 1a病毒颗粒筛选干扰HCV 1a病毒繁殖以治疗肝脏疾病的潜在治疗剂的方法。

    Nucleic acid vaccines for prevention of flavivirus infection
    85.
    发明授权
    Nucleic acid vaccines for prevention of flavivirus infection 有权
    用于预防黄病毒感染的核酸疫苗

    公开(公告)号：US07417136B1

    公开(公告)日：2008-08-26

    申请号：US09701536

    申请日：1999-06-03

    申请人： Gwong-Jen J. Chang

    发明人： Gwong-Jen J. Chang

    IPC分类号： C07H21/04 ,  A61K39/12

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/53 ,  C07K16/1081 ,  C07K2319/02 ,  C12N2770/24022 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2333/18 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/53 ,  Y02A50/60

    摘要： The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.

    摘要翻译： 本发明包括含有编码黄病毒M和E蛋白抗原的转录单位的核酸分子。 黄病毒包括日本脑炎病毒，登革热，黄热病毒和圣路易脑炎病毒。 当核酸位于合适的宿主细胞中时，特别是当宿主细胞是受试者的细胞时，核酸起到提供M和E蛋白抗原的作用。 本发明还包括其活性剂是核酸的疫苗。 本发明还包括当培养的宿主细胞含有含有转录单位的核酸分子时。 本发明另外包括通过向受试者施用含有含有本发明的转录单位的核酸分子的有效量的疫苗免疫受试者免受黄病毒感染的方法。

    IDENTIFICATION AND CHARACTERIZATION OF HCV REPLICON VARIANTS WITH REDUCED SUSCEPTIBILITY TO HCV-796, AND METHODS RELATED THERETO
    86.
    发明申请
    IDENTIFICATION AND CHARACTERIZATION OF HCV REPLICON VARIANTS WITH REDUCED SUSCEPTIBILITY TO HCV-796, AND METHODS RELATED THERETO 审中-公开
    具有降低HCV-796易感性的HCV REPLICON变体的鉴定和表征及其相关方法

    公开(公告)号：US20080182895A1

    公开(公告)日：2008-07-31

    申请号：US11842312

    申请日：2007-08-21

    申请人： Anita Y.M. Howe ,  Rajiv Chopra

    发明人： Anita Y.M. Howe ,  Rajiv Chopra

    IPC分类号： A61K31/343 ,  C12Q1/00 ,  A61P31/12

    CPC分类号： G01N33/5767 ,  A61K31/343 ,  A61K31/7056 ,  A61K45/06 ,  G01N2333/18 ,  A61K2300/00

    摘要： The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and/or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection.

    摘要翻译： 本发明提供降低出血频率，降低耐药水平并延缓出现治疗抗性丙型肝炎病毒感染的方法，通过给予受试者，组合或串联地将肝炎抑制剂 C RNA依赖性RNA聚合酶NS5B，例如苯并呋喃，如5-环丙基-2-（4-氟苯基）-6 - [（2-羟乙基）（甲基磺酰基）氨基] -N-甲基-1-苯并呋喃-3 （HCV-796）和至少一种另外的抗丙型肝炎药物，例如利巴韦林产品或免疫调节剂，例如干扰素产物。 此外，本发明涉及监测丙型肝炎病毒感染的治疗过程，监测和预测丙型肝炎病毒感染的方法的方法，以及鉴定具有降低的抗丙型肝炎病毒反应可能性的个体的方法 治疗。 这些方法使用丙型肝炎病毒RNA依赖性RNA聚合酶NS5B的序列和/或结构来鉴定治疗抗性丙型肝炎病毒感染，特别是苯并呋喃（例如HCV-796）治疗抗性丙型肝炎病毒感染的出现 。

    Purified active HCV NS2/3 protease
    87.
    发明授权
    Purified active HCV NS2/3 protease 有权

    公开(公告)号：US07264811B2

    公开(公告)日：2007-09-04

    申请号：US10650585

    申请日：2003-08-28

    申请人： Daniel Lamarre ,  Louise Pilote

    发明人： Daniel Lamarre ,  Louise Pilote

    IPC分类号： A61K39/29 ,  C12P21/00

    CPC分类号： C07K14/005 ,  C12N9/506 ,  C12N2770/24222 ,  C12Q1/37 ,  G01N33/6893 ,  G01N2333/18 ,  G01N2500/00 ,  G01N2500/04

    摘要： A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a chaotropic agent; and b) refolding the purified protease by contacting it with a reducing agent and lauryldiethylamine oxide (LDAO) in the presence of reduced concentration of chaotropic agent or polar additive. The invention further comprises a method for activating this refolded inactive NS2/3 protease by adding an activation detergent. This method produces large amounts of the active NS2/3 protease to allow small molecules and ligands to be screened as potential inhibitors of NS2/3 protease, which may be useful as therapeutic agents against HCV.

    METHODS FOR DETECTING FLAVIVIRUS INFECTION
    88.
    发明申请
    METHODS FOR DETECTING FLAVIVIRUS INFECTION 有权
    检测FLAVIVIRUS感染的方法

    公开(公告)号：US20070166701A1

    公开(公告)日：2007-07-19

    申请号：US11424127

    申请日：2006-06-14

    申请人： Gwong-Jen Chang

    发明人： Gwong-Jen Chang

    IPC分类号： C12Q1/70

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/53 ,  A61K2039/70 ,  C07K16/1081 ,  C07K2319/02 ,  C12N2770/24022 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12Q1/701 ,  G01N33/56983 ,  G01N2333/18 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/53 ,  Y02A50/60

    摘要： The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.

    摘要翻译： 本发明包括分离的核酸，其含有转录单位，其编码一种黄病毒和第二种黄病毒的免疫原性黄病毒抗原的信号序列。 本发明还包括核酸和蛋白质疫苗以及该疫苗用于免疫受试者免受黄病毒感染的用途。 本发明还提供由本发明的核酸编码的抗原，响应抗原引发的抗体以及抗原和/或抗体在检测黄病毒或诊断黄病毒感染中的用途。